Abstract:Background: CD19 and CD20 are B-cell lineage-specific antigens expressed on the cell surface of most B-cell lymphomas. While CD20 is acquired during late stages of B-cell lymphogenesis and is then lost upon differentiation into plasma cells, CD19 expression covers the entire spectrum of early B-cell genesis and maturation. CD20-targeting agents have been broadly integrated into the therapeutic armamentarium for B-cell lymphomas. More recently, CD19-targeting agents have emerged as promising alternatives with demonstrated therapeutic value. Given the imminent availability of both CD19 and CD20 targeted therapies, and potential for combinational approaches, we studied the surface expression of these antigens at the single-cell level on lymphoma cells and benign background lymphoid subsets from biopsy specimens. Methods: Flow cytometric analysis (seven-color) was performed on biopsy specimens from 47 patients with newly diagnosed B-cell lymphomas, including diffuse large B-cell lymphoma (n=15), follicular lymphoma (n=15), marginal zone lymphoma (n=9), mantle cell lymphoma (n=9), Burkitt lymphoma (n=2), and unclassifiable low-grade B-cell lymphoma (n=2). Small lymphocytic lymphoma was intentionally excluded, given its well-described loss of CD20 expression. Biopsies from eight additional patients with persistent/recurrent B-cell lymphomas after anti-CD20 therapy (greater than 6 months after last dose) were also evaluated. Thresholds for CD19 or CD20 antigen positivity were defined for each case, based on the 95th percentile fluorescence intensity of the respective marker on tumor-infiltrating T-cells (internal negative control). In addition, CD19 or CD20 fluorescence intensities of tumor cells were normalized to background benign B-cells (internal positive control) using the median fluorescence ratio (MFR). Results: Both CD19 and CD20 were highly expressed on CD20 treatment naïve tumor cells, with a slightly higher median percentage of positive tumor cells for CD19 (98%) compared with CD20 (93%) (p=0.003), and one case lacking CD20 expression. When compared with background benign B-cells, CD20 was frequently overexpressed on tumor cells (mean MFR=1.8), while CD19 expression was overall similar to background benign B-cells (mean MFR=0.9) (p=0.001). As the surface density of CD20 on benign B-cells is reportedly higher than CD19 (~100,000 vs ~20,000 molecules per cell, respectively), these findings are consistent with a higher density of surface CD20 than CD19 on most B-cell lymphomas. However, CD20 expression was more heterogeneous (within individual patient samples and across patients), with a higher median percentage of CD20-negative tumor events (median=0.5%, range=0-98%) compared with CD19-negative events (median=0%, range=0-28%) (p=0.003). Interestingly, expression of CD19 within the CD20-negative tumor subsets was largely preserved (mean % CD19-positive events=97.86%, min=40%). In addition, percentages of CD19/CD20 double-negative tumor events were very small (median=0%, range=0-4.9%), and only detectable in 15 cases (32%). Of eight additional cases studied post-anti-CD20 immunotherapy (6-84 months after last dose), the percentage of antigen-positive events by tumor cells was largely preserved for both CD19 (median=99.6%, range=93.5-100%) and CD20 (median=95.7%, range=55.6-100%), similar to the pre-therapy cohort. Conclusions: CD19 and CD20 are both highly and consistently expressed in B-cell lymphomas. While CD20 has a higher average density of surface molecules per tumor cell, CD19 expression is more homogenous and is preserved in small CD20-negative tumor subsets and after anti-CD20 targeted therapy. These findings support the clinical evaluation of anti-CD19 immunotherapies and combinational therapies targeting both surface antigens. Disclosures Horna: MorphoSys AG: Research Funding. Nowakowski:Selvita: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Bayer: Consultancy, Research Funding; Curis: Research Funding; F. Hoffmann-La Roche Ltd: Research Funding; Genentech, Inc.: Research Funding; MorphoSys: Consultancy, Research Funding; NanoString: Research Funding. Endell:MorphoSys AG: Employment, Patents & Royalties. Boxhammer:MorphoSys AG: Employment, Patents & Royalties.

CD20+ T cells in monoclonal B cell lymphocytosis and chronic lymphocytic leukemia: frequency, phenotype and association with disease progression

Clinical and Biological Significance of De Novo CD5+ Diffuse Large B-cell Lymphoma in Western Countries.

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia

Direct or reverse correlations within the expression of activation, differentiation or T-B cooperation molecules on chronic lymphocytic leukemia B cells

Characterization of Regulatory T Cells in Patients with B-cell Chronic Lymphocytic Leukemia.

Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion

The role of CD20+ T cells: Insights in human peripheral blood

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

CD11c+ B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy

Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia

Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia

Molecular map of chronic lymphocytic leukemia and its impact on outcome

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.

Cluster of Differentiation Markers and Human Leukocyte Antigen Expression in Chronic Lymphocytic Leukemia Patients: Correlations and Clinical Relevance

Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms

Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma